Why Opioids Fail in Nerve Pain: Nerve Injury Breaks the Opioid System's Control Over the Pain Peptide Substance P

Nerve injury completely abolished the ability of μ-opioid receptors to inhibit substance P release from pain-sensing nerve fibers in the spinal cord of rats — explaining why opioids work poorly for neuropathic pain. In contrast, this opioid-mediated inhibition of substance P release remained intact in rats with inflammatory pain and in untreated rats. The loss of opioid control was not caused by fewer opioid receptors on nerve fibers — their numbers remained unchanged. Instead, the opioid receptors appeared to lose their ability to signal properly after nerve injury, even though they were still physically present.

Researchers used rats with chronic constriction injury (CCI) of the sciatic nerve as a neuropathic pain model and complete Freund's adjuvant (CFA) injection as an inflammatory pain model. Substance P release in the spinal cord was measured indirectly by tracking NK1 receptor internalization — when substance P is released, it binds NK1 receptors, which are then pulled inside the cell. The μ-opioid agonist DAMGO was tested for its ability to inhibit substance P release in spinal cord slices. Opioid receptor expression was assessed by immunofluorescence colocalization with substance P in dorsal root ganglion neurons.

It's a well-known clinical problem that opioids are much less effective for neuropathic pain (from nerve damage) than for inflammatory pain. This study provides a molecular explanation: nerve injury disrupts the opioid receptor's ability to suppress the release of substance P — a key pain-transmitting neuropeptide — in the spinal cord. Understanding this mechanism could lead to strategies to restore opioid sensitivity in neuropathic pain or to develop alternative approaches that bypass this broken signaling pathway.

The opioid crisis has highlighted the need for better pain treatments, and the poor efficacy of opioids for neuropathic pain is both clinically frustrating and scientifically important. This study reveals that the problem isn't too few opioid receptors but broken receptor signaling — a more subtle and potentially fixable defect. Understanding exactly which signaling steps fail after nerve injury could lead to drugs that restore opioid receptor function or bypass the broken pathway entirely. This is particularly important as the field moves toward mechanism-based pain treatment rather than one-size-fits-all approaches.

This is a rat study using an indirect measure of substance P release (NK1 receptor internalization). The CCI model, while well-established, may not perfectly replicate all forms of human neuropathic pain. The study demonstrates loss of opioid receptor signaling but does not fully elucidate the specific signaling mechanisms that are disrupted. The findings are specific to μ-opioid receptors and substance P — other opioid receptors and neurotransmitter systems may be affected differently.